Ibrutinib Maintenance Therapy Shows Benefit in MCL Following Induction Therapy
The 3-year progression-free survival rate was 94% and the 3-year overall survival rate was 97%.
Oncology Nurses Are Uniquely Qualified to Meet the Needs of Patients With Lung Cancer
As with all patients with cancer, providing care for those with lung cancer involves both physiological and psychological aspects.
Cabozantinib Lengthens PFS in Pretreated Patients With Neuroendocrine Tumors
The median progression-free survival with cabozantinib was 8.3 months vs 3.2 months with placebo among patients with extra-pancreatic neuroendocrine tumors.
Delivering Teclistamab in the Outpatient Setting
Freshta Poupal, RN, and Frannie Bell, NP, share their experiences with teclistamab in clinical practice.
How I Counsel Patients About Lung Cancer Screening
A lung cancer screening navigator offers their perspective on shared decision-making.
Innovative Project Reduces Operating–Room-Related Pressure Injuries by 50.5%
An initiative led by nurses helped reduce operating-room pressure injuries and saved their institution an estimated $80,210 per year.
FDA Grants Pembrolizumab New Biliary Tract Cancer Indication
The FDA has approved pembrolizumab in combination with chemotherapy as a treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
Oncology Care Model: What Did We Learn?
The Oncology Care Model did not significantly improve care, yet patients were satisfied with their care and many oncologists overcame their hesitancy towards value-based models.
FDA Approves Toripalimab Regimens to Treat Adults With Nasopharyngeal Carcinoma
The FDA has approved toripalimab, with cisplatin and gemcitabine, and as a monotherapy, to treat adults with nasopharyngeal carcinoma.
Amivantamab/Chemo Elicits Responses in EGFR NSCLC That Has Progressed On Osimertinib
Patients who received amivantamab plus lazertinib and chemotherapy achieved a median progression-free survival of 8.3 months.
Frontline Atezolizumab/Chemo Shows PFS Benefit in Advanced/Recurrent Endometrial Cancer
The median progression-free survival was not reached with atezolizumab plus chemotherapy vs 6.9 months in the placebo group of patients with advanced or recurrent endometrial cancer.
Managing Early Satiety in MPNs
Amanda Smith, a registered nurse with Huntsman Cancer Institute, discusses the impact that early satiety can have on patients with myeloproliferative neoplasms and the role nurses play in helping patients manage this symptom.
Phase 3 Trial Supports Amivantamab Plus Lazertinib Over Osimertinib in Advanced EGFR+ NSCLC
The median progression-free survival was 23.7 months with the combination vs 16.6 months with osimertinib alone.
177Lu-PSMA-617 Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
The median radiologic progression-free survival was 12.02 months in the 177Lu-PSMA-617 group vs 5.59 months in the androgen receptor pathway inhibitor change group.
Certain Patients With Advanced/Metastatic NSCLC Derive PFS Benefit With Dato-DXd
Datopotamab deruxtecan improved progression-free survival in select subsets of patients with advanced or metastatic non–small-cell lung cancer.
PFS Significantly Improves With Dato-DXd in HR+, HER2- Metastatic Breast Cancer
Patients with metastatic hormone receptor-positive breast cancer treated with datopotamab deruxtecan experienced a statistically significant and clinically meaningful improvement in progression-free survival.
FDA Approves Ivosidenib to Treat Myelodysplastic Syndromes With IDH1 Mutation
Ivosidenib, a targeted therapy, has been approved for patients with relapsed or refractory myelodysplastic syndromes and an IDH1 mutation.
Sotorasib Plus Panitumumab Shows Potential in Refractory KRAS G12C+ mCRC
Sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer.
Tisotumab Vedotin Reduces Risk of Death by 30% in Recurrent/Metastatic Cervical Cancer
The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.
Induction Chemotherapy Improves Chemoradiation Success in Locally Advanced Cervical Cancer
Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.
Adding Nivolumab to Chemotherapy Improves Survival Rates in Metastatic Urothelial Carcinoma
Nivolumab plus gemcitabine-cisplatin improved overall and progression-free survival in unresectable or metastatic urothelial carcinoma.
Enfortumab Vedotin/Pembrolizumab May Be New SOC in Frontline Urothelial Cancer
For the first time, a new therapeutic regimen outperformed chemotherapy in improving overall survival in frontline urothelial cancer.
Durvalumab/Chemo Maintenance Followed by Olaparib Confers PFS Advantage in Endometrial Cancer
Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.
Amivantamab Significantly Improves Progression-Free Survival in EGFR exon 20 insertion–positive NSCLC
Amivantamab plus chemotherapy nearly doubled the progression-free survival in patients with EGFR Exon 20-mutated non–small-cell lung cancer.
Frontline Selpercatinib Doubles PFS in RET Fusion-Positive NSCLC
In the intention-to-treat population, the median progression-free survival was 24.8 months with selpercatinib vs 11.2 months.
New Data Support Selpercatinib as Standard of Care in Advanced RET+ Medullary Thyroid Cancer
The median progression-free survival was not reached with selpercatinib vs 16.8 months with other kinase inhibitors.
Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC
Adjuvant alectinib significantly improved disease-free survival in patients with ALK-positive, early-stage, non–small-cell lung cancer.
Neoadjuvant, Adjuvant Nivolumab Improve EFS in Resectable NSCLC
Treatment with neoadjuvant nivolumab, followed by adjuvant nivolumab after surgery, led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.
Entrectinib Is Approved for Pediatric Patients with NTRK+ Solid Tumors
The FDA has approved entrectinib to treat pediatric patients ages 1 month and older with NTRK-positive solid tumors.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512